You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科興製藥(688136.SH):GB08注射液I期臨牀試驗完成首例受試者入組
格隆匯 06-17 19:40

格隆匯6月17日丨科興製藥(688136.SH)公佈,全資子公司深圳科興藥業有限公司研發的“GB08注射液”I期臨牀研究成功完成首例受試者入組給藥。GB08注射液是公司首個自主研發的I類創新藥,是公司根據臨牀患者需求、基於兒童生長激素缺乏症而自主研發的一款Fc融合蛋白長效化生長激素,公司GB08注射液按治療用生物製品1類“創新型生物製品”申報。公司通過DNA重組技術,將人生長激素(hGH)基因與IgG4亞型Fc段基因連接後表達,形成具有同源二聚體蛋白結構的創新藥物,顯著提高了產品安全性及患者的用藥便利性和依從性,未來如成功研發上市將為兒童生長激素缺乏症患者帶來新的治療手段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account